DNMT3A and B-cell chronic lymphocytic leukemia: In CLL patients from the Global group, further experiments are required to better understand how the tumor repressors DNMT3A, TET1/2 but also MBD2/4 are dysregulated, and the consequences of this repression on disease progression.